Loading...
Uploaded by MedPageToday on Feb 1, 2008
Robert G. Maki, M.D., Ph.D., Memorial Sloan-Kettering Cancer Centerhttp://www.medpagetoday.comORLANDO -- In the post-imatinib (Gleevec) era, treatment of gastrointestinal stromal tumors has shifted from serial surgeries to refinement of kinase inhibitor dosing, according to this presentation from the ASCO-GI symposium here.
Education
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)